The prevalence of epilepsy in China is approximately 7‰, based on which the number of people with epilepsy in China is estimated to be no less than 9 million. More than 60% of Chinese epilepsy patients are children and adolescents, and because of the long and recurrent course of epilepsy, the physical and mental health of patients is seriously threatened, which brings a heavy burden to families and society. In recent years, as China’s population ages, the incidence of cerebrovascular disease, dementia, and neurodegenerative diseases has increased. Particularly, the incidence of epilepsy has been on the rise in the elderly population over the age of 50. Approximately there are 400,000 new cases in China each year. Since the number of people with epilepsy is still growing at a faster rate each year, individuals, families and society will be seriously affected.

At present, epilepsy is mainly treated with medication, and if epilepsy patients use medication in a standardized way, about 70% of them can have their condition well controlled.

Levetiracetam was first developed by UCB under the trade name of Keppra^®. As a first-line drug in the field of epilepsy treatment, levetiracetam was first marketed in the United States in 1999 in tablet form, and the extended-release tablet form was approved by the FDA in 2008, which is now widely regarded as the gold standard drug for epilepsy treatment.

Keppra was approved for marketing in China in November 2006. In 2009, after the expiration of the patent, generic drugs by Chinese companies were marketed, but Keppra still occupied a major market share. The dosage forms of levetiracetam include tablet, oral solution and injection. Among them, levetiracetam tablets have the main market share and the fiercest market competition with increasing generic drugs.

According to CRI’s market research, the sales value of levetiracetam in the Chinese market continued to rise from 2016 to 2019. In 2020, the COVID-19 outbreak prevented Chinese healthcare facilities from functioning properly. And as the various dosage forms of levetiracetam are prescription drugs in China, the total sales value of levetiracetam declined to approximately CNY319 million (USD49.1 million) with a CAGR of approximately 2.3% from 2016 to 2020.

CRI expects that from 2021 to 2025, China’s levetiracetam market will show a recovery growth in both sales volume and value due to the effective control of COVID-19 and the resumption of proper operation of healthcare facilities. The number of patients with epilepsy in China will continue to rise because of factors such as the accelerated pace of life and work and poor lifestyle behaviors like late nights, alcohol abuse, and the increasingly aging population, driving up both sales volume and value of levetiracetam in the Chinese market.

Topics Covered:

• Impact of COVID-19 on China’s Levetiracetam Market
• Development Environment of Levetiracetam in China
• Sales Volume of Levetiracetam in China
• Sales Volume and Value of Levetiracetam in China by Region
• Major Levetiracetam Manufacturers in China and Their Market Shares
• Sales Price of Levetiracetam in China
• Prospects of China’s Levetiracetam Market, 2021-2025

The post Research Report on China’s Levetiracetam Market, 2021-2025 first appeared on CRI Report.

In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another.

In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China’s Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.

CRI expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to CRI’s market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.

Topics Covered in Investigation Report on China’s Pregabalin Market 2021-2025

• -The impact of COVID-19 on China’s Pregabalin market
• – Sales value of China’s Pregabalin 2016-2020
• – Competitive landscape of China’s Pregabalin market
• – Prices of Pregabalin in China
• – Prices of Pregabalin in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Pregabalin market
• – Prospect of China’s Pregabalin market from 2021 to 2025

Investigation Report on Chinese Pregabalin Market, 2020-2024

The post Investigation Report on China’s Pregabalin Market 2021-2025 first appeared on CRI Report.